The objectives of this study were to evaluate baseline sympathetic nerve activity as well as the mechanisms of sympathetic overactivity in mild chronic renal insufficiency hypertension. Seven hypertensives with mild renal insufficiency, seven hypertensives with normal renal function and seven normotensives, age and weight-matched were studied on one session to evaluate baseline muscle sympathetic nerve activity measured in the peroneal nerve. The mild renal insufficiency hypertensives and the hypertensives with normal renal function were also studied to evaluate arterial baroreflex control of muscle sympathetic nerve activity assessed by increasing and decreasing blood pressure through continuous infusion of phenylephrine and sodium nitroprusside respectively. Baseline muscle sympathetic nerve activity was significantly higher in mild renal insufficiency hypertensives (34 bursts/min) when com-
Introduction
Hypertension is an important presenting feature of chronic renal disease and, although it is considered to be largely volume-dependent, there is evidence that sympathetic overactivity might contribute to its physiopathology. [1] [2] [3] Converse et al 3 demonstrated sympathetic overactivity in end-stage haemodialysis patients, most of them were hypertensives.
However, it is not known whether this overactivity is due to hypertension or to chronic renal insufficiency and whether it can be detected as early as in the predialysis phase of mild chronic renal insufficiency.
There may be defects in the ability of the cardiovascular system to respond to sympathetic nerve activity. Most studies of autonomic function have used indirect measurements. In fact, chronic renal insufficiency patients show impairment in the bradycardic response to hypertensive stimulae; this impairment is expressed by low reflex sensitivity. 4 However, it is not known whether baroreflex control of sympathetic nerve activity in chronic renal insufficiency hypertension is abnormal.
The aim of this study was to evaluate sympathetic nerve activity as well as the mechanisms involved in mild chronic renal insufficiency hypertension.
Subjects and methods

Subjects
The study sample consisted of 21 individuals, seven hypertensives with mild renal insufficiency, seven hypertensives with normal renal function and seven normotensives (Table 1 ). All subjects gave informed consent to participate in this study, which was approved by our institutional ethics committee on human research. All subjects were free of secondary renal disease due to a systemic pathology, secondary hypertension and other systemic diseases. All normotensives were free of cardiovascular and other systemic diseases based on a medical history and physical examination. 
Treatment, diet and activities
For all subjects currently being treated for hypertension (n = 14), antihypertensive medications were discontinued for at least 48 h before the study. All subjects continued their normal daily activities and diet.
Chemical measurements
Serum creatinine and urea were measured by autoanalyzer ASTR-4 (Beckman Instruments, Los Angeles, CA, USA), sodium and potassium levels were measured by spectrophotometry (Instrumentations Laboratory, IL-143, MA, USA). Haematocrit was quantified by microhaematocrit method and haemoglobin, plasma renin activity was measured by radioimmunoassay (REN-CT2/CIS: Biointernational, France), creatinine clearances were performed over a 24-h period.
Echocardiographic measurements
M-mode and bidimensional echocardiograms were obtained using the average of at least five consecutive cardiac cycles. 5 Studies were performed using Aloka SSD system model 860 and 725 devices (Aloka Co, Tokyo, Japan). The left ventricular mass was measured using the cube function formula 6 whereas the left ventricular mass index was calculated by dividing the left ventricular mass by the body surface area. Upper normal limits for the main echocardiographic variables were defined according to the methods of Ganau et al 7 the left ventricular mass index (LVMI) as 134 g/m 2 for men and 110 g/m 2 for women.
Experimental methods and sessions
Subjects were familiarised with the techniques and procedures before beginning the study. For each subject, identification of an appropriate site to measure sympathetic nerve activity (SNA; peroneal nerve posterior to the fibular head) was followed by a 10-min rest period. All subjects were studied in a supine position and were not sedated. Heart rate, blood pressure, respiratory movements and efferent sympathetic nerve activity were recorded during the experimental sessions. Heart rate was derived from an electrocardiogram (KD 281-045072: Dayton, OH, USA), blood pressure was measured with an automatic device (Finapress 2300: Ohmeda, Englewood, CO, USA) during the last half of each minute. Respiratory movements were recorded by Pneumotrace. Sympathetic nerve activity was recorded on a directwriting multichannel physiological recorder (Model RS 3800: Gould Inc, Cleveland, OH, USA) at paper speed of 5 mm/s through microneurography from a muscle nerve fascicle of the peroneal nerve posterior to the fibular head. 8, 9 All the baseline recordings were made during 10 minutes.
Arterial baroreflex control
After baseline recordings, baroreflex control of sympathetic nerve activity and heart rate were evaluated in mild renal insufficiency hypertensives and hypertensives with normal renal function by monitoring blood pressure increases and decreases in response to increasing doses of phenylephrine and sodium nitroprusside, respectively. Study drugs were administered intravenously using a continuous infusion method (Harvard apparatus infusion/ withdrawal pump, MA, USA). All measurements of SNA, heart rate and blood pressure were made during a 10-min continuous intravenous infusions of increasing doses (0.25, 0.5 and 1.0 g/kg/min) of phenylephrine 1% (University of Sao Paulo General Hospital, Sao Paulo, Brazil) and sodium nitroprusside (sodium nitroprusside: E Merck, Darmstadt, West Germany). The final dose of each vasoactive drug was followed by a rest period to allow variables (SNA, heart rate and blood pressure) to return to baseline levels.
Baroreflex gain was analysed by recording the most marked sympathetic and haemodynamic responses during each dose, thus when the neural discharge and the arterial blood pressure responses to vasoactive drugs appeared more evident.
Data analysis
Baroreflex gain for each subject was estimated by least-squares linear regression of values for diastolic blood pressure and SNA (expressed as a percent of control), heart rate, and mean arterial pressure.
Mean arterial pressure was calculated as diastolic pressure plus one-third of pulse pressure. Differences between mild renal insufficiency hypertensives and hypertensives baroreflex gain were assessed with unpaired t-test.
Differences between groups were assessed with one-way analysis of variance with repeated measurements and multiple range tests (TukeyKramer). The Mann-Whitney U-Test was applied when normal distribution of data could not be assumed. Spearman Rank Correlation was applied Values are mean ± s.e.m. *P Ͻ 0.05 vs NT; **P Ͻ 0.05 vs HT.
to correlate data. Data are expressed by mean plus minus standard error. A P value less than 0.05 was considered statistically significant.
Results
As shown in Table 2 , microneurographic records of baseline sympathetic nerve activity were 34 ± 4 bursts/min in mild renal insufficiency hypertensives, 24 ± 1 bursts/min in hypertensives with normal renal function and 16 ± 1 bursts/min in normotensives. Sympathetic nerve activity was significantly different (P Ͻ 0.05) in mild renal insufficiency hypertensives when compared to hypertensives and normotensives and among hypertensives when compared to normotensives (Figure 1 ). Figure  2 shows representative baseline recordings from one subject in each group.
Sympathetic and haemodynamic responses during each 10-min period of increasing doses of phenylephrine, results were as follows: in mild renal insufficiency hypertensives, sympathetic discharge responses were 19 ± 4, 13 ± 4 and 9 ± 4 bursts/min. Systolic blood pressure measured 187 ± 12, 180 ± 9 and 190 ± 10 mm Hg, and diastolic blood pressure measured 115 ± 6, 115 ± 5 and 117 ± 6 mm Hg. Mean Journal of Human Hypertension arterial pressure measured 138 ± 7, 136 ± 6 and 141 ± 7 mm Hg, and heart rate measured 63 ± 4, 63 ± 4 and 60 ± 2 bpm.
In hypertensives, sympathetic discharge responses were 19 ± 3, 11 ± 3 and 6 ± 2 bursts/min. Systolic blood pressure measured 156 ± 3, 164 ± 7 and 171 ± 4 mm Hg, and diastolic blood pressure measured 96 ± 4, 101 ± 4 and 106 ± 4 mm Hg. Mean arterial pressure measured 116 ± 4, 122 ± 4 and 128 ± 3 mm Hg, and heart rate measured 65 ± 3, 62 ± 2 and 58 ± 2 bpm.
Sympathetic and haemodynamic responses during each 10-min period of increasing doses of sodium nitroprusside, results were as follows: in mild renal insufficiency hypertensives sympathetic discharge responses were 51 ± 7, 51 ± 4 and 60 ± 1 bursts/min. Systolic blood pressure measured 153 ± 9, 142 ± 16 and 152 ± 24 mm Hg, and diastolic blood pressure measured 93 ± 9, 88 ± 8 and 103 ± 13 mm Hg. Mean arterial pressure measured 107 ± 7, 106 ± 10 and 110 ± 13 mm Hg, and heart rate measured 84 ± 5, 91 ± 4 and 101 ± 4 bpm.
In hypertensives, sympathetic discharge responses 37 ± 4, 46 ± 5 and 56 ± 7 bursts/min. Systolic blood pressure measured 147 ± 5, 140 ± 6 and 141 ± 5 mm Hg, and diastolic blood pressure measured 94 ± 3, 87 ± 4 and 85 ± 4 mm Hg. Mean arterial pressure measured 112 ± 3, 105 ± 5 and 104 ± 5 mm Hg, and heart rate 76 ± 3, 83 ± 5 and 88 ± 4 bpm.
Baroreflex gain, estimated by the least-squares linear regression of values for diastolic blood pressure and sympathetic nerve activity, was (in absolute values) 15.2 in hypertensives vs 2.6 in mild renal insufficiency hypertensives (P Ͻ 0.05) and 6.3 vs 8.2 during phenylephrine and nitroprusside, respectively ( Figure 3 ). Baroreflex gain, estimated by the least-squares linear regression of values for mean blood pressure and heart rate, was also statistically significant during phenylephrine.
Serum creatinine was higher in mild renal insufficiency hypertensives (P Ͻ 0.05) when compared to the other groups. Arterial blood pressure was significantly different in hypertensives and mild renal insufficiency when compared to normotensives. Creatinine clearance was 36 ± 5 ml/min/1.73 m 2 in mild renal insufficiency hypertensives and 110 ± 5 ml/min/1.73 m 2 in hypertensives (P Ͻ 0.05). Plasma renin activity was 12 ± 5 ng/ml/h and 0.6 ± 0.3 ng/ml/h respectively (P Ͻ 0.05; Table 3 ).
Left ventricular hypertrophy was evaluated by two-dimensional echocardiogram and showed LVMI 119 ± 26 g/m 2 in mild renal insufficiency hypertensives and 64 ± 6 g/m 2 in hypertensives with normal renal function (P Ͻ 0.05; Table 3 ).
Baseline sympathetic nerve activity was positively correlated to systolic and diastolic blood pressure, serum creatinine levels, and plasma renin activity (P Ͻ 0.05). LVMI correlated positively to plasma renin activity (P Ͻ 0.05). Values are mean ± s.e.m. *P Ͻ 0.05 vs HT.
Discussion
The main finding of the present study is that mild renal insufficiency hypertensives showed elevated sympathetic nerve activity compared to hypertensives and normotensives with normal renal function. It is well known the unfavourable role of increased sympathetic activity in cardiovascular disease. Converse et al, 3 studying 18 chronic renal failure haemodialysis patients, 14 of those patients having concurrent hypertension, showed sympathetic overactivity compared to normal subjects and anephrics. Sympathetic overactivity correlated positively to mean arterial pressure. Converse et al 3 concluded that chronic renal failure might be accompanied by reversible sympathetic activation, that appears to be mediated by an afferent signals arising in the failing kidneys. In other studies involving nephrectomised rats, it was demonstrated that afferent nerve resection prevented arterial hypertension and progression of renal disease. 10, 11 Sympathetic hyperactivity may be related to renin-angiotensin system. Experimental evidence has indicated that sympathetic nervous system and renin-angiotensin system interact in order to stimulate each other. 13 In our study, SNA correlated positively to plasma renin, activity and mild renal insufficiency hypertensives showed higher levels of plasma renin activity compared to hypertensives with normal renal function. In this study LVMI positively correlated to plasma renin activity but not to sympathetic activity. In spite of this, it is well known that elevated angiotensin II levels correlate significantly with the presence of left ventricular hypertrophy. 17 A number of clinical and experimental studies have demonstrated a close relationship between the level of adrenergic activity and the development of left ventricular hypertrophy. [14] [15] [16] [17] Catecholamines play an important role in the devel-opment and maintenance of left ventricular hypertrophy. Noradrenaline is implicated in the development of left ventricular hypertrophy. Catecholamines have been shown to promote protein synthesis, collagen deposition, myocardial fibrosis and left ventricular hypertrophy. 18, 19 Sympathetic hyperactivity may be related to arterial baroreceptor sensitivity. An experimental study in a rat model of renal failure showed that the slope of the regression line relating delta heart rate to delta blood pressure after phenylephrine administration was significantly less than in the normal group, indicating a reduction of baroreflex sensitivity in the setting of uraemia. 20 Baroreflex sensitivity was found significantly abnormal in non-dialysed patients. 21 Tomiyama et al 22 studying baroreflex sensitivity in renal failure concluded that reduced sensitivity correlated positively with hypertension. Lilley et al 4 showed in chronic renal insufficiency patients an impairment in the bradycardic response to hypertensive stimuli and this impairment is expressed by low reflex sensitivity. According to Meyrelles et al, 23 baseline sympathetic nerve activity values were significantly higher in hypertensives than in normotensives. The evaluation of arterial baroreflex gain showed a decreased value in hypertensives but it was statistically significant neither for the phenylephrine nor to the nitroprusside. In this study, baroreflex control of SNA and heart rate was evaluated by continuous infusions of phenylephrine and sodium nitroprusside. We found significant differences in baroreflex gain, with mild renal insufficiency hypertensives showing a blunted baroreflex gain when compared to hypertensives. Results suggested, therefore, that bradycardic response in mild renal insufficiency hypertensives be blunted. It is known the attenuating effect of angiotensin II on baroreflex sensitivity. 24 Moreira et al 25 have reported the existence of a close relationship between overactivity of renin-angiotensin system and the impairment of baroreflex control of heart rate in rats with renal hypertension. Reduction in baroreflex sensitivity present in the acute phase of 2K 1C hypertension in rats is mediated, at least in part, by renin-angiotensin system activation. 26 Sudden changes in arterial pressure typically evoke much smaller reflex changes in heart rate in uraemic patients than in healthy individuals. This reflex attenuation appears greatest in uraemic patients with hypertension but may also be found in uraemic patients with normal blood pressure. 27 In conclusion, this study demonstrated that mild renal insufficiency hypertensives exhibit elevated baseline sympathetic nerve activity and blunted arterial baroreflex gain suggesting that the reduction in baroreflex gain could be one of the mechanisms involved in hypertension. Another mechanism possibly implicated is the renin-angiotensin system overactivity.
